MORRISTOWN, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc ., a venture backed clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, today announced that the clinical dataset from the Company’s Phase 1 study of its lead asset, RE104, will be presented in both a podium and poster at the Anxiety and Depression Association of America (ADAA) Conference taking place April... Read More

WILMINGTON, N.C., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. , a venture backed clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today announced that Greg Mayes, Chief Executive Officer, will participate in the following investor conferences. Please contact your representative to schedule a 1x1 meeting... Read More

WILMINGTON, Del., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. , a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 2 study of RE104, a novel serotonergic... Read More

TORONTO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) (" Reunion " or the " Company "), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions and MPM BioImpact (" MPM ") are pleased to announce the completion of the previously announced plan of arrangement (the " Arrangement ")... Read More

TORONTO, July 14, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) (" Reunion " or the " Company "), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions is pleased to announce that, earlier today, the Ontario Superior Court of Justice (Commercial List) granted a final order approving the proposed... Read More

TORONTO, July 13, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) (" Reunion " or the “ Company ”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, is pleased to announce the voting results of the special meeting of shareholders of Reunion held yesterday, July 12, 2023 (the " Meeting "). At... Read More

Common Shareholders to Receive Consideration of US$1.12 Per Share in Cash from the Arrangement Agreement with MPM BioImpact; Special Shareholder Meeting Scheduled July 12 Presented Encouraging Phase 1 Final Analysis at American Society of Clinical Psychopharmacology Annual Meeting TORONTO, June 29, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“ Reunion ” or the " Company ”), a clinical-stage... Read More

Reunion Common Shareholders to Receive Consideration of US$1.12 Per Share in Cash Represents a 43.1% Premium to the 30-Day Volume Weighted Average Price Reunion Presents Encouraging Phase 1 Final Analysis at American Society of Clinical Psychopharmacology Annual Meeting, Enabling Advancement into Phase 2 in 2H 2023 TORONTO, June 01, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“ Reunion ” or... Read More

TORONTO, April 25, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that management will host a corporate presentation at the 2023 Bloom Burton & Co. Healthcare Investor Conference being held on... Read More

TORONTO, April 25, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that on April 19, 2023, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“NASDAQ”)... Read More

- Seasoned Psychiatrist and Global Pharmaceutical R&D Executive with Over Two Decades of Experience in Clinical Development, Including at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb and Sunovion Pharmaceuticals TORONTO, April 03, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing innovative and... Read More

TORONTO, March 27, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that the Company’s first-in-human results for lead asset, RE104, have been accepted for a poster presentation at the 2023 American... Read More

TORONTO, March 13, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, has filed a lawsuit today against Mindset Pharma Inc. (“Mindset”) in the United States District Court for the District of New Jersey, alleging that... Read More

TORONTO, March 07, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today announced that management will participate in the Oppenheimer Annual Healthcare Conference as part of the biotechnology virtual corporate... Read More

Company Completed Phase 1 Interim Data Analysis for Lead Asset, RE104, Which Showed Strong Safety and Tolerability with Differentiated Profile; Final Data Anticipated in Mid-2023 Continued to Strengthen Executive Team; Named Dr. Robert Alexander as Chief Medical Officer At December 31, 2022, Reunion Held CAD $32.4 Million in Cash and Cash Equivalents TORONTO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc.... Read More

TORONTO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that the Company plans to release its business update and financial results for Reunion’s fiscal 2023 third quarter ended December 31, 2022, before... Read More

TORONTO, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc . (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that it has appointed Robert Alexander, M.D. as the Company’s Chief Medical Officer, effective immediately. Dr. Alexander will report to Greg... Read More

TORONTO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today announced that the Company has completed the interim data analysis for its Phase 1 clinical trial with lead asset RE104, a unique 4-OH-DiPT prodrug. RE104 is... Read More

Company Plans to Report Phase 1 Interim Analysis for RE104 in Q1 2023 and Include Data Differentiating its Safety, Tolerability and Pharmacodynamic Profile from Other Psychedelics in Clinical Development On Track to Dose First Patient in Phase 2 Postpartum Depression Study in 2H 2023 President and CEO Presenting at Biotech Showcase in San Francisco on Jan. 9 TORONTO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience... Read More

TORONTO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today announced it will be participating in the following investor conferences in December 2022. Stifel Canada's The Future of Healthcare Conference Date: Wednesday, December 7, 2022 Time:... Read More

TORONTO, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the “Company”), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today announced that it has entered into an equity distribution agreement with Canaccord Genuity to establish an at-the-market equity facility. Pursuant to the... Read More

Completed RE104 Phase 1 prespecified dose cohorts and on track to deliver interim Phase 1 analysis in the first calendar quarter of 2023. Appointed Greg Mayes as President and Chief Executive Officer, with Joseph del Moral moving into the role of Chairman. Announced reinforcement of the executive leadership team with the addition of highly experienced pharmaceutical professionals: Edward Smith as Chief Financial Officer, Dr.... Read More

Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) ("Reunion" or the “Company”), a biopharmaceutical company committed to developing innovative therapeutic solutions for underserved mental health conditions, announced today that it plans to release its business update and financial results for its fiscal 2023 second quarter ended September 30, 2022, before market open on Monday, November 14, 2022. The Company will conduct a... Read More

Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) ("Reunion" or the “Company”), a biopharmaceutical company committed to developing innovative therapeutic solutions for underserved mental health conditions, announced today that the Company will participate in two upcoming conferences in November. Hanson Wade 5 th Annual Neuropsychiatric & Psychedelics Drug Development Summit Moderator: Greg Mayes, President & CEO, Reunion... Read More

Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) ("Reunion" or the “Company”), a biopharmaceutical company committed to developing innovative therapeutic solutions for underserved mental health conditions, announced today that it has appointed Edward Smith as the Company’s Chief Financial Officer and Aviva Asnis-Alibozek as Vice President, Medical Affairs, effective immediately. Both Mr. Smith and Dr. Asnis-Alibozek will... Read More

Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the “Company”), a leader in novel serotonergic psychedelic drug development committed to innovating proprietary therapeutic solutions for mental health conditions, announced today that the Company’s President and CEO, Mr. Greg Mayes, will participate on a panel at this year’s Horizons Perspectives on Psychedelics conference, taking place at the New York... Read More

Reunion Neuroscience Inc . (TSX: REUN, NASDAQ: REUN) (" Reunion " or the “ Company ”), a leader in novel psychedelic drug development committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds, today announced that Ronan Levy has resigned as Director of the Company and Paula Amy Hewitt has resigned as General Counsel & Corporate Secretary,... Read More

Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) ("Reunion"), or (“the Company”), a global leader in the discovery and development of innovative psychedelic-inspired therapeutics for improved mental health outcomes, today announced that management will participate in the Cantor Neurology & Psychiatry Conference taking place on October 6-7, 2022 at the Ritz Carlton, San Francisco. The Reunion management team will... Read More

Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) (" Reunion " or the “ Company ”) today announced the results of the votes held at its September 29, 2022 Annual General and Special Meeting of shareholders (the “ Meeting ”). The total number of common shares represented by shareholders present in person or by proxy at the Meeting was 5,073,132, representing 43.57% of the Company’s 11,642,953 outstanding common shares... Read More

Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the “Company”), a leader in novel psychedelic drug development committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds, announced the appointment of Greg Mayes as President and Chief Executive Officer. As Reunion’s new President and CEO, Mr. Mayes’ initial focus will be on the... Read More

Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) ("Reunion"), or (“the Company”), a global leader in the discovery and development of innovative psychedelic-inspired therapeutics for improved mental health outcomes, today announced it will participate in two upcoming investor conferences in September 2022. H.C. Wainwright 24 th Annual Global Investment Conference Reunion’s management team will present at a virtual... Read More

Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) ("Reunion"), or (“the Company”), a global leader in the discovery and development of innovative of psychedelic-inspired therapeutics for improved mental health outcomes, today announced it has scheduled its 2022 Annual General Meeting of Shareholders for September 29, 2022 at 10:00 AM ET. Shareholders of record on August 23, 2022 will be able to vote and ask questions... Read More

Reunion Neuroscience Inc. (formerly, Field Trip Health Ltd., the " Company " or “ Reunion ”), a global leader in the discovery and development of innovative of psychedelic-inspired therapeutics for improved mental health outcomes, is pleased to announce that its common shares (the " Shares ") will commence trading on the Toronto Stock Exchange (“ TSX ”) under the ticker symbol “REUN” at the opening of the market on August... Read More

Completed corporate reorganization, separating the Field Trip Discovery and Field Trip Health divisions into two separate companies. Field Trip Discovery renamed Reunion Neuroscience Inc. (“Reunion” or the “Company”), and will remain listed on the NASDAQ Stock Market and Toronto Stock Exchange under new ticker symbol “REUN”. Field Trip Health renamed Field Trip Health & Wellness Ltd. (“Field Trip H&W”) and has received... Read More

Field Trip Health Ltd. has been renamed "Reunion Neuroscience Inc." and remains listed on the NASDAQ Stock Market and Toronto Stock Exchange under the ticker symbol "FTRP" with such ticker symbol changing to "REUN" Field Trip Health & Wellness Ltd. to be listed on the TSX Venture Exchange under ticker symbol “FTHW” First day of trading for both Reunion and Field Trip Health & Wellness expected to occur on or about August 17,... Read More

Field Trip Health Ltd. (TSX: FTRP, Nasdaq: FTRP) ("Field Trip" or the “Company”), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for its fiscal 2023 first quarter for the three-month period ended June 30, 2022, after market close on Monday, August 15, 2022. The Company will conduct a conference call and webcast to discuss its results the... Read More

Field Trip Health & Wellness Ltd. to list on the TSX Venture Exchange, with first day of trading expected to occur on or about August 17, 2022. Field Trip Discovery to be renamed Reunion Neuroscience Inc., remaining listed on the NASDAQ Stock Market and Toronto Stock Exchange. Field Trip Health Ltd. (TSX: FTRP, Nasdaq: FTRP) (" Field Trip ", the " Company "), a global leader in the development and delivery of psychedelic... Read More

First Dosings completed in Australia Provides Update on Pending Spin-Out and Renaming to Reunion Neurosciences Announces 5:1 Share Consolidation Ratio Field Trip Health Ltd . (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip" or the “Company”), a global leader in the development and delivery of psychedelic therapies, announced today the first successful dosings in the Phase 1 Clinical Study entitled “A Double-Blind,... Read More

Completed strategic review and announced intention to separate the Field Trip Discovery and Field Trip Health divisions into two independent public companies. Earned patient services revenues of $1.7 million in fiscal fourth quarter, an increase of 26.7% over the prior quarter and 228% year over year. Full year patient services revenue was $4.9 million, up from $0.96 million in the same period of the prior year. At March 31,... Read More

Closing of arrangement subject to regulatory approvals, including conditional listing approval by the TSX Venture Exchange. Closing of the arrangement expected to occur in August. Also announces closing of subscription receipt offering. Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip" or the "Corporation"), a global leader in the development and delivery of psychedelic therapies, today announces that... Read More

Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip" or "Corporation"), a global leader in the development and delivery of psychedelic therapies, today announced that on June 27, 2022, its shareholders approved both the Arrangement Resolution, the Concurrent Financing Resolution and the SpinCo Incentive Plan Resolution (each as defined in the Circular (each as defined below)) at its special meeting of... Read More

Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that Field Trip’s Co-founder and Executive Chairman, Ronan Levy, and Chief Scientific Officer, Dr. Nathan Bryson, will participate in a live fireside chat at the H.C. Wainwright 1 st Annual Mental Healthcare Conference taking place June 27, 2022. Date: June 27,... Read More

Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for its fiscal fourth quarter and full year ended March 31, 2022, after market close on Wednesday, June 29, 2022. The Company will conduct a conference call and webcast to discuss its results the following morning,... Read More

Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) (the " Company " or " Field Trip "), a global leader in the development and delivery of psychedelic therapies, announced today that it has agreed to increase its participation in the concurrent financing, in support of, and in connection with, the spin-out of its clinics business to Field Trip Health & Wellness Ltd. (“ SpinCo ”) by way of a plan of arrangement (the "... Read More

Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a leader in the development and delivery of psychedelic-assisted psychotherapy with 12 locations across North America and Europe, and Nue Life Health (‘Nue Life’), a leader in mental wellness telehealth and at-home ketamine treatments, announced today the launch of Field Trip at Home™ Powered by Nue Life, which provides ketamine treatments from the comfort of a... Read More

Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that Field Trip’s management team will participate in two investor conferences in May 2022. 2022 Bloom Burton & Co. Healthcare Investor Conference: Date: May 2-3, 2022 Location: Toronto Presentation date & time: May 2, 2022 at 11:00am E.T. Webcast link: Click here... Read More

Transaction will create two distinct emerging leaders in the psychedelics industry, one providing personalized care and the other developing next generation psychedelic therapies. Shareholders of Field Trip will receive shares of each company. Company to host a conference call on Friday, April 29, 2022 at 8:30 a.m. ET. Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) (the " Company "), a global leader in the... Read More

Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that Field Trip’s management team will participate in the following investor conferences in April 2022. Sequire Cannabis & Psychedelic Virtual Conference: Date: April 20 at 3:00pm ET Registration & Webcast: Click Here KCSA Virtual Psychedelics Conference: Date:... Read More

Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, today announced that the U.S. Patent and Trademark Office (“USPTO”) has granted the Company a patent for claims related to FT-104 (informally known as “Isoprocin Glutarate”), Field Trip’s first novel psychedelic molecule in development. Claims in the patent application titled, “Tryptamine... Read More

Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that management will present at the Maxim Group 2nd Annual Virtual Growth Conference, hosted by M-Vest, taking place March 28-30, 2022. A recording of Field Trip’s presentation will be available to view on demand beginning at 9:00 a.m. ET on Monday, March 28th. To... Read More

Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that management will be presenting at the 34th Annual Roth Conference taking place on March 13-15, 2022 in California. Field Trip’s Chief Scientific Officer, Dr. Nathan Bryson, will participate in the “Immunotherapy For The Mind” panel on March 15 th at 10:00a.m.... Read More

Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic-assisted psychotherapy, today announced a strategic partnership with Cerebral, the fastest growing online mental health platform. The companies are launching a partnership where Cerebral clinicians... Read More

Earned patient services revenues of $1,360,811, an increase of 50% over the prior quarter and 330% year over year. At December 31, 2021, Field Trip had approximately $74.5 million in unrestricted cash and cash equivalents and short-term investments. Received Notice of Allowance for US Patent Application Covering FT-104 (Isoprocin Glutarate), a more soluble, stable prodrug form of the psychedelic molecule 4-HO-DiPT. Launched... Read More

Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that Field Trip’s Co-Founder and CEO, Joseph del Moral, and Chief Scientific Officer, Dr. Nathan Bryson, will participate in Citi’s Psychedelic Drug Video Call Series. Hosted by Neena Bitritto-Garg, Vice President Research Analyst, Biotech, the fireside chat with... Read More

Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Field Trip’s patent application No. 17/364,047 for claims related to FT-104 (informally known as “Isoprocin Glutarate”), Field Trip’s first novel psychedelic molecule in development.... Read More

Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, today announced that it will begin making applications for Canadians in need to access psilocybin-assisted and MDMA-assisted therapy through Health Canada’s Special Access Program (SAP). The announcement follows amendments to the SAP announced in the Canada Gazette on January 5, 2022,... Read More

Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that Field Trip’s Co-Founder and CEO, Joseph del Moral, and Chief Scientific Officer, Dr. Nathan Bryson, will participate in a virtual fireside chat at the H.C. Wainwright Bioconnect Virtual Conference taking place January 10-13, 2022. A recording of Field Trip’s... Read More

Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, today announced the launch of its Site Management Organization Services (“SMO Services”). The SMO Services will enable companies and researchers developing psychedelic therapies to use Field Trip’s world class facilities, and expertly trained medical and therapy teams, to conduct clinical... Read More

Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that management will present at H.C. Wainwright’s 2nd Annual Psychedelics Conference and Stifel’s 2nd Annual Future of Healthcare Conference in December. H.C. Wainwright’s 2nd Annual Psychedelics Conference Field Trip’s Co-Founder and CEO, Joseph Del Moral, and... Read More

Announced plans to advance FT-104, its novel psychedelic compound, to clinic for Treatment-Resistant Depression and Postpartum Depression as the lead indications. Initiated a new pipeline research program focused on discovering novel psychedelics with a reduced cardiovascular risk profile compared to classic psychedelics (the “ FT-200 Group ”) and filed a provisional patent in connection to the composition of matter for the... Read More

Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that during the month of November management will attend the Microdose Wonderland: Miami Conference and present at the Stifel 2021 Virtual Healthcare Conference and the Jefferies London Healthcare Conference. Wonderland: Miami Conference Field Trip’s Co-founder... Read More

Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for the fiscal second quarter ended September 30, 2021, after market close on Monday, November 15, 2021. The Company will conduct a conference call and webcast to discuss its results the following morning, Tuesday,... Read More

Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today the opening of their Seattle clinic, their sixth in the United States, along with the recent opening of a location in Fredericton, NB, and the imminent opening of a location in Vancouver, BC. As the largest provider of psychedelic-assisted therapies globally, Field Trip... Read More

Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; Nasdaq: FTRP) (" Field Trip "), today announced the voting results from its Annual General and Special Meeting of Shareholders held on Friday, September 24, 2021. A total of 59.09% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting. On a vote by ballot, the following nine nominees proposed by the Corporation... Read More

Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; Nasdaq: FTRP) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, today announced it will participate in the H.C. Wainwright 23 rd Annual Global Investment Conference, the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit, the Maxim Group Mental Health Conference and the Cantor Virtual Global Health Conference in September 2021. H.C.... Read More

Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; NASDAQ: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today the lead indications for FT-104, its novel psychedelic compound in development, will be Treatment Resistant Depression (TRD) and Postpartum Depression (PPD). Field Trip today also announced that Anita H. Clayton, MD, Chair of Psychiatry and Neurobehavioral... Read More

The KAP Co-op program gives eligible therapists the ability to provide ketamine-assisted psychotherapy (KAP) to their patients at Field Trip Health Centers utilizing Field Trip’s medical teams for screening, prescribing and administration of ketamine. Training programs will provide both didactic and experiential training to therapists and medical professionals who wish to learn about KAP. Therapists who complete Field Trip’s... Read More

At June 30, 2021 had approximately $100 million in unrestricted cash and cash equivalents, funds held in trust and short-term investments Development of FT-104, a novel psychedelic molecule with pending patents, continues to progress with GMP production achieved The Company remains on track to meet milestone of 20 sites open or under construction by December 2021 TORONTO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Field Trip Health... Read More

Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for its first fiscal quarter ended June 30, 2021, after market close on Monday, August 16, 2021. The Company will conduct a conference call and webcast to review its results the following day, Tuesday, August 17 at 8:30... Read More

Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; OTCQX: FTRPF) ("Field Trip" or the “Company”), a global leader in the development and delivery of psychedelic therapies, announced today that it has received final approval from The NASDAQ Stock Market LLC (“NASDAQ”) to list its common shares on the NASDAQ Global Select Market. The Company’s shares will begin trading at market open on Thursday, July 29, 2021 with the ticker symbol... Read More

Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; OTCQX: FTRPF) ("Field Trip" or the “Company”), a global leader in the development and delivery of psychedelic therapies, announced today that it has received conditional approval from The NASDAQ Stock Market LLC (“NASDAQ”) to list its issued and outstanding common shares on the NASDAQ Global Select Market. Final approval of the listing is subject to the Company fulfilling any... Read More

Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; OTCQX: FTRPF) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that Ronan Levy, Co-Founder & Executive Chairman, will take part in a panel discussion and participate in one-on-one investor meetings at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit on July 13, 2021. The panel discussion, entitled “Emerging... Read More

Field Trip completes FY2021 as the largest vertically integrated psychedelics company positioned to be a leader in the emerging industry Continues to leverage its early mover opportunity by investing in its drug development strategy and the build out of a globally recognized brand of psychedelic-assisted therapy centers Closed FY2021 with $111,817,443 in unrestricted cash and cash equivalents, funds held in trust and... Read More

Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; OTCQX: FTRPF) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for its fiscal fourth quarter and full year 2021 ended March 31, 2021, after market close on Thursday, June 24, 2021. The Company will conduct a conference call and webcast to review its results the following day, Friday,... Read More

Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; OTCQX: FTRPF) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, today announced that it has completed initial drug metabolism and pharmacokinetic (“DMPK”) studies for FT-104, its novel psychedelic compound in development. In-vitro preclinical studies confirmed that metabolism of FT-104 is rapid and complete in several animal species, converting... Read More

Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; OTCQX: FTRPF) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, is pleased to announce that it has applied to list its common shares (the “Common Shares”) on the NASDAQ Stock Market (“NASDAQ”). “Psychedelics stand poised to disrupt modern psychiatry, and the NASDAQ is where world class companies whose ambition is disruption list to reach a global... Read More

Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, is pleased to announce that its common shares will commence trading on the Toronto Stock Exchange (“TSX”) under the ticker symbol “FTRP” and its warrants will trade under the symbol "FTRP.WT" at the opening of the market on June 7, 2021. In connection with the TSX listing, Field Trip’s... Read More

Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF) (" Field Trip "), a leader in the development and delivery of psychedelic therapies, is pleased to announce that it has received conditional approval to list its common shares and warrants on the Toronto Stock Exchange (TSX). The listing is subject to the company fulfilling certain requirements of the TSX in accordance with the terms of its conditional approval letter... Read More

Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF) (" Field Trip "), a leader in the development and delivery of psychedelic therapies, is pleased to announce the appointment of former US Senate Majority Leader Tom Daschle as a Special Adviser to the Company. Joseph del Moral, Chief Executive Officer of Field Trip, said, “Senator Daschle has participated in the development and debate of almost every major public... Read More

New, annual survey commissioned by Field Trip Health reveals that 1 in 4 Canadians self rate their current mental health as fair or poor, with women bearing the brunt of the fallout More than Eight in 10 Canadians report showing symptoms of depression Today, Field Trip Health Ltd. (CSE: FTRP) (CSE: FTRP.WT) (OTCQX: FTRPF) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, released the findings... Read More

The survey conducted by YouGov Plc found that: More than 8 in 10 Americans report showing symptoms of depression Many are turning to different substances and vices to cope Women are bearing the brunt of the fallout worse than men But close to 1 in 2 would try or be interested in learning more about psychedelic therapies for their mental health Field Trip Health Ltd. (CSE: FTRP, OTCQX: FTRPF) (“Field Trip”) today announced... Read More

Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF) (" Field Trip "), a leader in the development and delivery of psychedelic therapies, is pleased to announce that its common shares are now eligible for electronic clearing and settlement through The Depository Trust Company ("DTC") in the United States. DTC is a subsidiary of The Depository Trust & Clearing Corporation, a United States company that manages the... Read More

Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today the opening of its fifth location in the United States in the city of Houston, TX. Located in the River Oaks District, the Houston location is the second Field Trip Health center to open this year. Field Trip also announced that it has entered into leases and has... Read More

Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF) (" Field Trip "), a leader in the development and delivery of psychedelic therapies, is pleased to announce that it has closed the bought deal short form prospectus offering previously announced on February 25 and 26, 2021, including the full exercise of the underwriters’ over-allotment option (the " Offering "). In connection with the Offering, Field Trip issued... Read More

Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF) (" Field Trip "), a leader in the development and delivery of psychedelic therapies, is pleased to announce today that, due to strong demand, it has agreed with a syndicate of underwriters led by Bloom Burton Securities Inc. (collectively, the " Underwriters "), to increase the size of its previously announced C$50,000,015 “bought deal” offering of common shares.... Read More

Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF) (" Field Trip "), a leader in the development and delivery of psychedelic therapies, is pleased to announce it has entered into an agreement with Bloom Burton Securities Inc. (" Bloom Burton " or the " Lead Underwriter ") on behalf of a syndicate of underwriters (together with the Lead Underwriter, the " Underwriters "), pursuant to which the Underwriters have agreed... Read More

Q3 2021 patient services revenues of $316,329 represent a 235% increase over the previous quarter Field Trip continues to advance development of FT-104, a novel psychedelic molecule with pending patents by accelerating activities in manufacturing and preclinical toxicology to acquire the data required for Phase 1 studies. 5 Field Trip Health centers are in operation, with Amsterdam, Houston and San Diego under construction... Read More

Field Trip Health Ltd. (CSE: FTRP, FTRP.WT, OTCQX: FTRPF) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for its third fiscal quarter ended December 31, 2020, after market close on Tuesday, February 16, 2021. The Company will conduct a conference call and webcast to review its results the following day, Wednesday, February... Read More

Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF) (" Field Trip "), a leader in the development and delivery of psychedelic therapies, is pleased to announce the official opening of the Field Trip Natural Products Limited Research and Development Laboratory for Psychedelic Fungi in Mona, Jamaica. The research facility, which is opening as part of Field Trip’s previously announced strategic partnership with the... Read More

Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF) (" Field Trip "), a leader in the development and delivery of psychedelic therapies, is pleased to announce its common shares have been approved for trading on the OTCQX® Best Market (“ OTCQX ”) retaining its current symbol FTRPF, effective as of the opening of trading today, January 28, 2021. Field Trip’s shares and warrants continue to trade on the Canadian... Read More

Field Trip Health Ltd. (CSE: FTRP, OTCBB: FTRPF) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today the opening of their fifth location in the United States in the city of Atlanta, GA, one of many locations that Field Trip is planning to open in 2021. Located in the Glenwood Park neighborhood, the Atlanta location is the first Field Trip Health center to open this year,... Read More